GlaxoSmithKline plc (LON:GSK) declared a dividend on Wednesday, October 25th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.25) per share on Thursday, January 11th. This represents a yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th. The official announcement can be seen at this link.

Shares of GlaxoSmithKline plc (LON GSK) traded up GBX 9.50 ($0.13) on Friday, reaching GBX 1,361 ($17.96). 7,047,222 shares of the company’s stock traded hands.

GlaxoSmithKline plc (LON:GSK) last released its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. The business had revenue of GBX 784.30 billion during the quarter.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/04/glaxosmithkline-plc-gsk-to-issue-dividend-of-gbx-19.html.

A number of research analysts recently issued reports on the company. J P Morgan Chase & Co restated a “neutral” rating and set a GBX 1,570 ($20.72) price objective on shares of GlaxoSmithKline plc in a research report on Monday, October 2nd. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($23.23) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, October 25th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price target on GlaxoSmithKline plc and gave the stock a “buy” rating in a research report on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.38) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research report on Wednesday, September 6th. Finally, Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($23.75) price target on shares of GlaxoSmithKline plc in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of “Hold” and an average target price of GBX 1,619.75 ($21.37).

In related news, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were bought at an average cost of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner bought 473 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were bought at an average cost of GBX 1,518 ($20.03) per share, for a total transaction of £7,180.14 ($9,474.98). Insiders have bought 1,574 shares of company stock worth $2,398,888 over the last ninety days.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Dividend History for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.